Iconovo AB is a Sweden-based company, which offers inhalation solutions for pharmaceutical companies. Solutions are based on the Companyâ€™s device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

10-23 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
15/10/26	SEK 0.9960	0.00%	17,471
14/10/26	SEK 0.9960	-0.20%	43,139
13/10/26	SEK 0.9980	-8.02%	118,647
12/10/26	SEK 1.085	0.00%	20,028
09/10/26	SEK 1.085	+6.90%	55,409

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Evolution of Analysts' Estimates - EPS - Iconovo AB

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Iconovo AB

Company calendar

Market Closed - Nasdaq Stockholm 20:00:00 15/10/2026 +04			5-day change	1st Jan Change
0.9960 ^SEK	0.00%		-1.87%	-12.63%

08-20	Iconovo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-22	Iconovo AB (Publ.) and Lonza Group Ag Sign Strategic Collaboration Agreement	CI

Market Cap	95.79M 9.61M 8.58M 7.97M 7.25M 13.65M 910M 13.89M 37.48M 475M 36.07M 35.31M 1.52B	P/E 2026 *	-11.1x	P/E 2027 *	-2.62x
Enterprise Value	58.79M 5.9M 5.27M 4.89M 4.45M 8.38M 559M 8.53M 23M 292M 22.14M 21.67M 933M	EV / Sales 2026 *	2.03x	EV / Sales 2027 *	-
Free-Float	41.24%	Yield 2026 *	-	Yield 2027 *	-

08-20	Iconovo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-22	Iconovo AB (Publ.) and Lonza Group Ag Sign Strategic Collaboration Agreement	CI
06-22	Iconovo, Lonza Finalize Long-term Strategic Collaboration	MT
04-24	Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-24	Iconovo Q1 net sales up at 0.7 mln SEK	RE
04-14	Iconovo appoints Anders Mañsson as CEO	RE
04-14	Iconovo AB Appoints Anders Månsson as Permanent CEO, Effective April 14, 2026	CI
03-17	Iconovo says no TO 1 was used for subscription	RE
03-02	Iconovo announces final outcome of rights issue	RE
02-25	Iconovo and Lonza sign LOI regarding strategic collaboration	RE
02-24	Iconovo AB (Publ.) and Lonza Signs LOI Regarding Strategic Collaboration	CI
02-12	Iconovo Q4 net sales SEK 504,000	RE
02-12	Iconovo AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

08-24	Iconovo: Still waiting for commercial proof – Q2 review	AQ
07-03	Iconovo AB (publ) reintroduces liquidity provider agreement with Pareto Securities AB	AQ
06-29	Iconovo terminates liquidity provider agreement	AQ
06-22	Iconovo and Lonza sign Strategic Collaboration Agreement	AQ
04-24	Iconovo: Limited progress – Q1 review	AQ

Iconovo AB Stock

Stocks

ICO

SE0010868943

Medical Equipment, Supplies & Distribution

Valuation: Iconovo AB

Chart: Iconovo AB

Latest news: Iconovo AB

Analysts' recommendations: Iconovo AB

Press Releases: Iconovo AB

Quotes and Performance

Price Extremes

Managers and Directors: Iconovo AB

Latest insider transactions

Medical Supplies

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

1 week	-1.87%
Current month	-18.69%
1 month	-19.02%
3 months	-5.14%
6 months	-11.47%
Current year	-12.63%

1 week	0.95	1.08
1 month	0.95	1.3
Current year	0.87	1.5
1 year	0.87	2.01
3 years	0.87	13
5 years	0.87	90
10 years	0.87	99.8

Manager	Title	Age	Since
Anders Månsson CEO	Chief Executive Officer	59	31/10/2025
Henrik Simonsen DFI	Director of Finance/CFO	63	01/04/2023
Mikael Arinder COO	Chief Operating Officer	62	01/01/2016

Director	Title	Age	Since
Mats Håkan Johansson CHM	Chairman	65	01/01/2013
Orest Lastow BRD	Director/Board Member	62	01/01/2013
Berndt David Lennart Axelsson BRD	Director/Board Member	67	01/01/2013

Date	Insider	Type	Main position	Quantity	% Market Cap.
22/09/22	Mats Håkan Johansson	Buy	Founder	500	0.0057%
21/09/22	Johan Wäborg	Buy	Chief Executive Officer	1,000	0.0113%
16/09/22	Agneta Walhagen	Buy	Director	840	0.0095%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ICONOVO AB	0.00%	-1.87%	-50.20%	-92.03%	9.61M
ABBOTT LABORATORIES	+2.29%	+6.28%	-19.13%	+15.20%	181B
MEDTRONIC PLC	+1.29%	+8.77%	+0.12%	+32.64%	117B
STRYKER CORPORATION	+4.12%	+5.87%	-20.70%	+13.71%	112B
ESSILORLUXOTTICA	+0.41%	+3.99%	-44.97%	-9.38%	76.56B
CENCORA, INC.	+1.56%	+6.24%	+6.82%	+80.66%	65.15B
HOYA CORPORATION	+2.83%	+2.43%	+16.00%	+68.74%	52.79B
BECTON, DICKINSON AND COMPANY	+2.58%	+6.02%	+3.74%	-25.10%	52.78B
IDEXX LABORATORIES, INC.	+3.43%	+6.63%	-14.39%	+28.39%	43.11B
MEDLINE INC.	+1.78%	+2.32%	-	-	32.08B
Average	+2.03%	+4.37%	-13.63%	+12.54%	73.29B
Weighted average by Cap.	+2.26%	+5.70%	-11.92%	+23.07%

	2026 *	2027 *
Net sales	29M 2.91M 2.6M 2.41M 2.2M 4.13M 276M 4.21M 11.35M 144M 10.92M 10.69M 460M	-
Net income	-6M -602K -537K -499K -454K -855K -57.03M -870K -2.35M -29.75M -2.26M -2.21M -95.21M	-37M -3.71M -3.31M -3.08M -2.8M -5.27M -352M -5.37M -14.48M -183M -13.93M -13.64M -587M
Net Debt	-37M -3.71M -3.31M -3.08M -2.8M -5.27M -352M -5.37M -14.48M -183M -13.93M -13.64M -587M	-44M -4.42M -3.94M -3.66M -3.33M -6.27M -418M -6.38M -17.22M -218M -16.57M -16.22M -698M